Cholangiogram of durvalumab-related sclerosing cholangitis as immune-mediated adverse event

IF 3.2 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepato‐Biliary‐Pancreatic Sciences Pub Date : 2025-02-12 DOI:10.1002/jhbp.12119

Naosuke Kuraoka, Tetsuro Ujihara, Shun Sakai

引用次数: 0

Abstract

Immune checkpoint inhibitor-related sclerosing cholangitis is most commonly associated with PD-1 or PD-L1 inhibitors. Kuraoka and colleagues report a novel case of cholangitis as an immune-mediated adverse event caused by durvalumab, with findings suggestive of the diagnosis observed on a cholangiogram obtained by endoscopic retrograde cholangiography.

Abstract Image

查看原文本刊更多论文

durvalumab相关硬化性胆管炎的胆管造影作为免疫介导的不良事件。

免疫检查点抑制剂相关的硬化性胆管炎最常与PD-1或PD-L1抑制剂相关。Kuraoka和他的同事报告了一个新的胆管炎病例，这是由durvalumab引起的免疫介导的不良事件，其发现提示了内镜逆行胆管造影获得的胆管造影的诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepato‐Biliary‐Pancreatic Sciences GASTROENTEROLOGY & HEPATOLOGY-SURGERY

自引率

10.00%

发文量

178

审稿时长

6-12 weeks

期刊介绍： The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.